Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
January 09, 2025 16:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 11:27 ET
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025 08:00 ET
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
January 07, 2025 08:00 ET
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
January 06, 2025 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report.
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
December 19, 2024 16:15 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
December 10, 2024 18:26 ET
|
Myriad Genetics, Inc.
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
December 10, 2024 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
December 10, 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines.
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024 16:05 ET
|
Myriad Genetics, Inc.
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium.